Cargando…
Unilateral interlaminar fenestration on the convex side provides a reliable access for intrathecal administration of nusinersen in spinal muscular atrophy: a retrospective study
BACKGROUND: As the first gene therapy for spinal muscular atrophy (SMA), nusinersen is supposed to be administrated via intrathecal injection regularly for a lifetime. However, for SMA patients with severe spinal deformities, bony fusion following posterior spinal instrumentation sets great obstacle...
Autores principales: | Wang, Zhen, Feng, Erwei, Jiao, Yang, Zhao, Junduo, Chen, Xin, Zhang, Haozhi, Liang, Jinqian, Li, Zheng, Cui, Xulei, Chen, Weiyun, Shen, Jianxiong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685557/ https://www.ncbi.nlm.nih.gov/pubmed/38031122 http://dx.doi.org/10.1186/s13023-023-02972-3 |
Ejemplares similares
-
Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience
por: Haché, Manon, et al.
Publicado: (2016) -
Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
por: Stolte, Benjamin, et al.
Publicado: (2018) -
Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy
por: Orbach, Rotem, et al.
Publicado: (2022) -
Ultrasound-guided interlaminar approach for nusinersen administration in patients with spinal muscular atrophy with spinal fusion or severe scoliosis
por: Wei, Cuijie, et al.
Publicado: (2023) -
Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)